Lucas Arruda

Company: CuraCell Holding AB

Job title: Chief Scientific Officer

Bio:

Dr. Lucas Arruda is the Chief Scientific Officer at CuraCell, where he leads the development of CytoPLY and CC 38—an advanced platform and clinical-stage TIL product designed to treat late-stage, immunologically cold solid tumors. Under his scientific leadership, CuraCell has presented promising clinical data from named-patient programs at both AACR and ISCT, underscoring the therapeutic potential of TILs in patients unresponsive to conventional therapies.

Seminars:

Understanding the State-of-Play of TIL Therapies Beyond Melanoma 9:30 am

Evaluating the unique antigenic landscapes and immune responses that hinder the translation of TIL therapies from melanoma to other tumor types Discussing innovative approaches to enhance TIL therapy efficacy across different tumor types Reviewing recent research and clinicalRead more

day: Workshop Day R&D Track AM